title: Clinical relevance of CYP3A5 genotype on maraviroc exposures.
authors.affiliation: Pfizer Inc., Clinical Pharmacology, New York, New York (M.V.); Pfizer Inc., Pharmacometrics, Sandwich, United Kingdom (L.M.); Pfizer Inc., Clinical Development, Groton, Connecticut (J.H.); and ViiV Healthcare, London, United Kingdom (A.C.) manoli.vourvahis@pfizer.com.
authors.forename: Manoli
authors.initials: M
authors.lastname: Vourvahis
authors.affiliation: Pfizer Inc., Clinical Pharmacology, New York, New York (M.V.); Pfizer Inc., Pharmacometrics, Sandwich, United Kingdom (L.M.); Pfizer Inc., Clinical Development, Groton, Connecticut (J.H.); and ViiV Healthcare, London, United Kingdom (A.C.).
authors.forename: Lynn
authors.initials: L
authors.lastname: McFadyen
authors.affiliation: Pfizer Inc., Clinical Pharmacology, New York, New York (M.V.); Pfizer Inc., Pharmacometrics, Sandwich, United Kingdom (L.M.); Pfizer Inc., Clinical Development, Groton, Connecticut (J.H.); and ViiV Healthcare, London, United Kingdom (A.C.).
authors.forename: Jayvant
authors.initials: J
authors.lastname: Heera
authors.affiliation: Pfizer Inc., Clinical Pharmacology, New York, New York (M.V.); Pfizer Inc., Pharmacometrics, Sandwich, United Kingdom (L.M.); Pfizer Inc., Clinical Development, Groton, Connecticut (J.H.); and ViiV Healthcare, London, United Kingdom (A.C.).
authors.forename: Andrew
authors.initials: A
authors.lastname: Clark
mesh_terms: D003510:Cyclohexanes / Q000493:pharmacokinetics*; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D023581:HIV Fusion Inhibitors / Q000493:pharmacokinetics*; D064368:Healthy Volunteers; D006801:Humans; D014230:Triazoles / Q000493:pharmacokinetics*
chemical_list: D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D051544:Cytochrome P-450 CYP3A
references.citation: Pharmacogenomics. 2004 Apr;5(3):243-72
references.pmid: 15102541
references.citation: Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:38-46
references.pmid: 18333864
references.citation: Nat Med. 2005 Nov;11(11):1170-2
references.pmid: 16205738
references.citation: N Engl J Med. 2008 Oct 2;359(14):1429-41
references.pmid: 18832244
references.citation: Drug Metab Dispos. 2014 Nov;42(11):1796-802
references.pmid: 25117426
references.citation: J Acquir Immune Defic Syndr. 2006 Jun;42(2):183-91
references.pmid: 16639345
references.citation: J Infect Dis. 2010 Mar 15;201(6):803-13
references.pmid: 20151839
references.citation: Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85
references.pmid: 16433896
references.citation: Antivir Ther. 2009;14(5):607-18
references.pmid: 19704163
references.citation: CPT Pharmacometrics Syst Pharmacol. 2013 Aug 14;2:e64
references.pmid: 23945605
references.citation: Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:86-94
references.pmid: 18333870
references.citation: Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32
references.pmid: 16251317
references.citation: J Pharmacol Exp Ther. 2005 Feb;312(2):583-91
references.pmid: 15523003
references.citation: Drug Metab Dispos. 2014 Jul;42(7):1163-73
references.pmid: 24737844